Literature DB >> 2936707

The pharmacokinetics and tissue penetration of teicoplanin.

C A McNulty, G M Garden, R Wise, J M Andrews.   

Abstract

The pharmacokinetics of teicoplanin were studied following a 440 mg intravenous dose in six male volunteers. The levels of the compound were measured in serum, blister fluid and urine. The mean serum level 0.5 h after injection was 44.6 mg/l falling to 3.6 mg/l at 49 h. The elimination half-life of teicoplanin from serum was 34.2 h and the apparent distribution half-life 1.5 h. Penetration into blister fluid was moderately fast, the mean maximum concentration (14.8 mg/l) occurring at 2.7 h, and the mean percentage penetration being 77.4%. Urinary recovery of the drug was 48.3% by 96 h.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2936707     DOI: 10.1093/jac/16.6.743

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment.

Authors:  Y Domart; C Pierre; B Clair; J J Garaud; B Regnier; C Gibert
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

2.  Binding of teicoplanin to human serum albumin.

Authors:  A Assandri; A Bernareggi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of teicoplanin.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

Review 4.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 5.  Teicoplanin: 10 years of clinical experience.

Authors:  M Trautmann; H Wiedeck; M Ruhnke; M Oethinger; R Marre
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

6.  Pharmacokinetics of teicoplanin in renal failure.

Authors:  C Falcoz; N Ferry; N Pozet; G Cuisinaud; P Y Zech; J Sassard
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

7.  Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections.

Authors:  M R Bibler; P T Frame; D N Hagler; R B Bode; J L Staneck; V Thamlikitkul; J E Harris; A Haregewoin; W E Bullock
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

8.  Clinical efficacy and safety of teicoplanin in the treatment of gram-positive infections.

Authors:  P Kempf; H Pompetzki; A Oppermann; R Wittenberger; J Siebert; J J Fell; H A Dieterich
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

9.  Pharmacokinetics of teicoplanin in pediatric patients.

Authors:  A Terragna; G Ferrea; A Loy; A Danese; A Bernareggi; L Cavenaghi; R Rosina
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

10.  Teicoplanin in the treatment of skin and soft tissue infections: results of a multicentre study.

Authors:  E Lang; M Földes; S Marghescu
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.